ClinicalTrials.gg
Not yet recruitingNCT07306884Updated Dec 29, 2025

Neurophysiological, Autonomic, and Sonographic Assessment of Diabetic Peripheral Neuropathy

An interventional study of Nerve conduction study and Nerve ultrasound in Diabete Mellitus and Peripheral (Sensorimotor) Diabetic Polyneuropathy, sponsored by Assiut University. Not yet recruiting at 1 site in Egypt. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-29.

Primary conditionDiabetic NeuropathiesRegistry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetic Neuropathies
Why
  1. The study's listed conditions name Diabetic Neuropathies, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Assiut University · Not applicable, Interventional, and Screening

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 31 studies in Diabetic Neuropathies with a site in Egypt — 9 open to participants now, 9 under way, none of them phase 3. Diabetic Neuropathies · Egypt.

Planned enrollment
7th of 22
75 · median 60
Started
2026
with 1 other
No phase
13 of 31
3 open now
Registered
29th of 31
by date
Lead sponsor
2 of 31
Assiut University

Among the 31 studies in Diabetic Neuropathies with a site in Egypt, this one is the 7th largest by planned enrollment of the 22 interventional ones that give a count, is one of 2 that started in 2026, is one of 13 with no phase, and was the 29th registered.

Diabetic Neuropathies

539 studies on the registry are indexed under Diabetic Neuropathies; 80 are open to participants now.

Browse Diabetic Neuropathies studies →

Open to participants now

9 of the 31 studies in Diabetic Neuropathies with a site in Egypt are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 52 Diabetic Neuropathies studies recruiting now, 21 (40%) set no upper age limit and 24 (46%) stop at 75 or younger; 6 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Diabetic Neuropathies with a site in Egypt, or all of them as a file.
02

Study summary

Diabetic peripheral neuropathy causes pain, sensory loss, and foot risk; multimodal assessment enables earlier diagnosis and improved patient management.

Read the detailed description

Diabetic peripheral neuropathy (DPN) is a prevalent and disabling complication of diabetes, associated with pain, sensory deficits, gait instability, and increased risk of foot ulcers and amputation. Conventional diagnostic methods, such as nerve conduction studies, primarily identify established disease and may overlook early or autonomic involvement. A multimodal assessment integrating neurophysiological, autonomic, and sonographic techniques offers the potential for earlier detection, improved diagnostic accuracy, and optimized patient management.

03

Conditions studied

  • Diabete Mellitus
  • Peripheral (Sensorimotor) Diabetic Polyneuropathy

Browse trials for

Keywords

  • Diabete Mellitus
  • Peripheral neuropathy
  • Neurophysiological studies
  • Nerve ultrasound
  • automatic assessment
04

In context

Diabetic Neuropathies Reclassified

539 studies on the registry are indexed under Diabetic Neuropathies; 80 are open to participants now.

This study's planned enrollment of 75 is above the median of 68 across 449 interventional studies indexed under Diabetic Neuropathies.

Browse Diabetic Neuropathies studies →

Lead sponsor

Assiut University is the lead sponsor of 5,094 studies on the registry; 2,187 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Compared within Diabetic Neuropathies, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Adults aged 18-75 years with type 1 or type 2 diabetes (with or without diabetic peripheral neuropathy), and age and sex-matched healthy controls

Exclusion criteria

Exclusion Criteria:

  • Other causes of neuropathy (e.g., CIDP, trauma, toxins, vitamin deficiencies), advanced renal failure,thyroid disease,chronic alcohol use, pregnancy,
  • presence of implanted cardiac devicesthat may interfere with autonomic testing
06

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
75 participants (estimated)

Study arms

  • Other
    Diabetic patients with symptomatic peripheral neuropathy.

    Diagnostic Test: Nerve conduction study · Diagnostic Test: Nerve ultrasound

  • Other
    Diabetic without any clinical features nor complaints of peripheral neuropathy

    Diagnostic Test: Nerve conduction study · Diagnostic Test: Nerve ultrasound · Diagnostic Test: Autonomic assessment

  • Other
    Healthy individuals.

    Diagnostic Test: Nerve conduction study · Diagnostic Test: Nerve ultrasound · Diagnostic Test: Autonomic assessment

Interventions

  • Diagnostic testNerve conduction study

    Nerve conduction studies (NCS) are widely regarded as the gold standard for evaluating large-fiber peripheral nerve function. They measure conduction velocity, latency, and amplitude, providing objective evidence of axonal loss or demyelination. While highly specific, NCS often detect abnormalities only in established diabetic peripheral neuropathy, limiting their sensitivity for early or subclinical disease.

  • Diagnostic testNerve ultrasound

    High-resolution ultrasound (HRUS) is a non-invasive imaging tool that allows structural evaluation of peripheral nerves. It can measure cross-sectional area (CSA), visualize fascicular pattern, and detect nerve enlargement or structural abnormalities. In diabetic peripheral neuropathy, HRUS provides complementary information to functional tests and may identify early or subclinical changes.

  • Diagnostic testAutonomic assessment

    Autonomic testing provides insight into small-fiber and autonomic nervous system function, often impaired early in diabetic peripheral neuropathy. Heart rate variability (HRV) during deep breathing and postural change is a simple, non-invasive method to detect cardiovascular autonomic dysfunction

07

What researchers measure

Primary outcomes

  1. Sensitivity of nerve conduction studies for diagnosing diabetic peripheral neuropathy

    Percentage of participants with clinically diagnosed diabetic peripheral neuropathy who have abnormal nerve conduction study results (reduced amplitude and/or reduced conduction velocity) at the baseline visit.

    Time frame: Baseline (single study visit)

Secondary outcomes

  1. Correlation between tibial nerve cross-sectional area and tibial motor conduction velocity

    Correlation coefficient between tibial nerve cross-sectional area measured by high-resolution ultrasound and tibial motor nerve conduction velocity at the baseline visit.

    Time frame: Baseline (single study visit)

08

Study locations

1 site
  • Department of Neurology, Faculty of Medicine,Assiut university
    Asyut, Asyut Governorate 71511, Egypt
09

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2026; primary completion for Jan 2027, 12 months later.

Of 138 non-industry interventional studies with no phase under Diabetic Neuropathies, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 24. This study's planned 12 months is close to that.

Counting every sponsor, half of 153 studies reached it within 11 months; a quarter within 6 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2025
First posted
Dec 29, 2025
StartEst.
Jan 2026
Primary completionEst.
Jan 2027
CompletionEst.
Feb 2027
Last update
Dec 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07306884
Lead sponsor
Assiut University
Responsible party
Dalia Rageh Daifallah Galal (Resident at Neurology and Psychiatry Department, Assiut University, Assiut University) — Principal investigator
First posted
Dec 29, 2025
Start date
Jan 2026 (estimated)
Primary completion
Jan 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Dec 29, 2025

Study contacts

Dalia Galal
Contact
daliarageh6@gmail.com
+201090463145
Nageh Fouly
study chair · Department of Neurology , Assiut University, Egypt

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion